These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 10912294

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H, Ehninger G, Schmidt H, Berner B, Reuss-Borst M, Waller HD, Müller CA, Einsele H.
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease.
    Tse JC, Moore TB.
    Pharmacotherapy; 1998 Jun; 18(5):988-1000. PubMed ID: 9758310
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Blockade of acute grade IV skin and eye graft-versus-host disease by anti-interleukin-2 receptor monoclonal antibody in genoidentical bone marrow transplantation setting.
    Ozşahin H, Tuchschmid P, Lauener R, Waldvogel K, Nadal D, Seger RA.
    Turk J Pediatr; 1998 Jun; 40(2):231-5. PubMed ID: 9677728
    [Abstract] [Full Text] [Related]

  • 10. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S, Nakaseko C, Nishimura M, Maruta A, Cho R, Ohwada C, Sakamaki H, Sao H, Mori S, Okamoto S, Miyamura K, Kato S, Kawase T, Morishima Y, Kodera Y, Japan Marrow Donor Program.
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S, Aker M, Shapira MY, Resnick I, Bitan M, Or R.
    Clin Transpl; 2003 Apr; ():275-82. PubMed ID: 15387119
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM.
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ganciclovir-mediated elimination of HSV-Tk+ T cells and cure of graft-vs-host disease in an allogeneic bone marrow transplantation model in the rat.
    Weijtens M, van Spronsen A, Hagenbeek A, de Weger R, Martens A.
    Exp Hematol; 2004 Oct; 32(10):962-9. PubMed ID: 15504552
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
    Chan GW, Gorgun G, Miller KB, Foss FM.
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):170-6. PubMed ID: 12652467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.